REGISTER
Fruquintinib-Serplulimab Shows First-Line Activity in nccRCC at ASCO GU 2026
Updated phase 2 data presented at ASCO GU 2026 suggest that first-line fruquintinib plus serplulimab may provide durable disease control with manageable toxicity in metastatic or unresectable non-clear cell renal cell carcinoma.

At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium, Prof. Jiwei Huang of Renji Hospital, Shanghai Jiao Tong University School of Medicine, reported updated results from a multicenter, single-arm phase 2 trial evaluating fruquintinib plus serplulimab in the first-line setting for metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC; abstract 422). The presentation, delivered during the oral abstract session on renal cell cancer and testicular cancer, addressed a persistent evidence gap in a biologically heterogeneous disease with few prospective treatment data.

Refractory nccRCC remains a first-line treatment challenge

Non-clear cell histologies account for roughly 20% to 30% of renal cell carcinomas and include papillary, chromophobe, TFE3-rearranged, and unclassified subtypes, among others. Compared with clear cell RCC, nccRCC is more clinically heterogeneous, and treatment decisions have often been extrapolated from clear cell studies rather than built on dedicated trials.

That lack of disease-specific evidence has left patients with metastatic or unresectable nccRCC with limited first-line options and generally poorer outcomes than those seen in clear cell disease. Investigators framed the combination of the selective VEGFR inhibitor fruquintinib and the PD-1 inhibitor serplulimab as a rational attempt to pair antiangiogenic therapy with immune checkpoint blockade in a setting where standard approaches remain unsettled.

Study design: multicenter single-arm phase 2 trial

The study (NCT05831891), led by Renji Hospital with participation from major Chinese cancer centers including Sun Yat-sen University Cancer Center, enrolled adults aged 18 to 80 years with pathologically confirmed metastatic or unresectable nccRCC, no prior systemic antitumor therapy, an ECOG performance status of 0 or 1, and adequate organ function. Thirty-eight patients were ultimately enrolled, close to the prespecified target of 39.

Patients received fruquintinib 5 mg orally once daily on a schedule of 2 weeks on treatment followed by 1 week off, together with intravenous serplulimab 4.5 mg/kg every 3 weeks, until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was progression-free survival (PFS) by RECIST 1.1, with objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (TRAEs) as secondary measures.

Key data: efficacy signals with durable disease control

At the data cutoff of September 30, 2025, median follow-up was 10 months (95% CI, 9.2-15.9). Median patient age was 53.5 years, 68.4% were men, and 44.7% had an ECOG performance status of 1. Histologies included papillary tumors in 50.0% of patients and unclassified disease in 18.4%; five patients had sarcomatoid features. The most common metastatic sites were lymph nodes (52.6%), lung (34.2%), and peritoneum (34.2%).

Progression-free survival and response outcomes

Median PFS had not yet been reached at the time of analysis, and the 9-month PFS rate was 87.3%, suggesting sustained disease control in a substantial proportion of treated patients. Among 36 response-evaluable patients, 1 complete response and 18 partial responses were observed, while 16 patients had stable disease. Three patients experienced rapid progression within 4 months of enrollment.

All 3 patients with rapid progression had sarcomatoid differentiation, an observation that may be clinically relevant but remains hypothesis-generating in a cohort of this size. The reported ORR was 52.8% (95% CI, 36.5-69.1), and the DCR was 97.2% (95% CI, 85.5-99.9). Together, these findings suggest meaningful antitumor activity in a population for whom robust first-line data remain scarce.

Safety profile remained manageable

Treatment-related adverse events of any grade occurred in 94.7% of patients, but most events were grade 1 or 2. One patient developed grade 3 aspartate aminotransferase elevation, and no grade 4 or higher TRAEs were reported. The most common TRAEs, each occurring in at least 15% of patients, were rash (28.9%), proteinuria (26.3%), hypertension (26.3%), hypothyroidism (21.1%), alanine aminotransferase or aspartate aminotransferase elevation (21.1% each), pyrexia (18.4%), and increased blood creatinine (15.8%).

Investigators reported no serious adverse events, no treatment-related deaths, and no permanent treatment discontinuations due to adverse events. Although the safety profile was consistent with the known toxicities of VEGFR inhibition and PD-1 blockade, the relatively short follow-up means cumulative or delayed immune-related toxicities still warrant continued observation.

A China-led regimen may broaden options, but unanswered questions remain

The updated data position fruquintinib plus serplulimab as a potentially relevant first-line option for metastatic or unresectable nccRCC, particularly in a field where prospective studies have lagged behind those in clear cell RCC. The study also highlights the growing contribution of Chinese cooperative groups to evidence generation in genitourinary oncology.

Still, the findings should be interpreted with caution. This was a single-arm study with a small sample size, histologic heterogeneity, and limited follow-up, and overall survival data were not mature. Whether the regimen will outperform existing targeted or immunotherapy-based approaches, or benefit all nccRCC subtypes equally, will require larger comparative studies. The poor outcomes seen in patients with sarcomatoid differentiation also underscore the need for better risk-adapted strategies.

Next steps

Longer follow-up will be needed to determine the durability of benefit and to clarify overall survival, duration of response, and outcomes by histologic subtype. A randomized phase 3 program would be the logical next step if these findings continue to hold, particularly because nccRCC remains an area of substantial unmet need in routine practice.

For now, the phase 2 data provide an early but notable signal that combined VEGFR inhibition and PD-1 blockade may help redefine first-line treatment for some patients with nccRCC. Whether that signal translates into a new standard will depend on confirmatory evidence.

0
0
Loading